Evaluation of in vitro SARS‐CoV‐2 inactivation by a new quaternary ammonium compound: Bromiphen bromide

Abstract

AbstractThe pneumonia (COVID‐19) outbreak caused by the novel coronavirus named severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), which unpredictably exploded in late December of 2019 has stressed the importance of being able to control potential pathogens with the aim of limiting their spread. Although vaccines are well known as a powerful tool for ensuring public health and controlling the pandemic, disinfection and hygiene habits remain crucial to prevent infection from spreading and maintain the barrier, especially when the microorganism can persist and survive on textiles, surfaces, and medical devices. During the coronavirus disease pandemic, around half of the disinfectants authorized by the US Environmental Protection Agency contained quaternary ammonium compounds (QACs); their effectiveness had not been proven. Herein, the in vitro SARS‐CoV‐2 inactivation by p‐bromodomiphen bromide, namely bromiphen (BRO), a new, potent, and fast‐acting QAC is reported. This study demonstrates that BRO, with a dose as low as 0.02%, can completely inhibit SARS‐CoV‐2 replication in just 30 s. Its virucidal activity was 10‐ and 100‐fold more robust compared to other commercially available QACs, namely domiphen bromide and benzalkonium chloride. The critical micellar concentration and the molecular lipophilicity potential surface area support the relevance of the lipophilic nature of these molecules for their activity.